Crown Princess Mette-Marit of Norway has been placed on a lung transplant waiting list, the Norwegian royal family announced. The decision reflects a serious decline in her respiratory function due to chronic obstructive pulmonary disease (COPD).

Mette-Marit, 51, has battled COPD for years. The condition progressively damages the lungs, making breathing increasingly difficult over time. When conservative treatments no longer manage symptoms effectively, transplantation becomes a medical option for select patients with end-stage disease.

Lung transplantation represents a significant medical intervention. Surgeons remove one or both diseased lungs and replace them with healthy organs from a deceased donor. The procedure offers patients with severe COPD a potential extension of life and improved quality of life, though it requires lifelong immunosuppressive medications and carries substantial risks including organ rejection.

The royal family's public disclosure of Mette-Marit's condition underscores the seriousness of her diagnosis. COPD develops when airways become inflamed and narrowed, typically from smoking or prolonged exposure to air pollution. Once diagnosed, the disease cannot be reversed, though medications and lifestyle changes can slow progression.

Transplant eligibility involves careful medical evaluation. Doctors assess lung function, overall health status, ability to comply with post-transplant care, and psychological readiness. Patients on waiting lists may wait months or years for suitable donor organs, depending on blood type, body size, and disease severity.

The announcement comes during a turbulent period for the Norwegian royal family, which has faced several public controversies. Despite these challenges, the royal household has prioritized transparent communication about Mette-Marit's health status.

For transplant patients, outcomes vary. Some experience significant functional improvement and extended survival. Others face complications including chronic rejection, infections related to immunosuppression,